Skip to main content
OCUL
NASDAQ Life Sciences

Ocular Therapeutix 10-Q: $94.8M Q3 Loss, $530.6M Cash, EyePoint Suit Settled

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$6.2
Mkt Cap
$1.448B
52W Low
$6
52W High
$16.44
52W Position info
3.3% above low
Off High info
62% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

OCUL is trading near its 52-week low of $6 (3.3% above the low).

Summary

Ocular Therapeutix's Q3 10-Q shows a $94.8 million net loss on $12.9 million of revenue, offset by $530.6 million in cash that funds operations into 2028 and the planned Q4 2026 AXPAXLI NDA. It also discloses the October 30 EyePoint lawsuit settlement at no cost and a SOL-R protocol change moving the primary endpoint to Week 40.


Key Events · Earnings and Guidance · OCUL

  • Q3 Loss Widens to $94.8M

    Net loss was $94.8 million, or $0.42 per share, versus $69.4 million, or $0.38 per share, a year earlier. Revenue fell to $12.9 million from $14.5 million as gross-to-net provisions rose to 57.7% of gross DEXTENZA sales.

  • R&D Jumps on Trial Enrollment

    Research and development expense rose to $74.8 million from $52.4 million, driven by HELIOS-3 and SOL-X enrollment plus added headcount. Total operating expenses were $110.7 million versus $83.2 million.

  • Cash Funds Runway Into 2028

    Cash and cash equivalents were $530.6 million at September 30, 2026, which the company says funds operating expenses, debt service and capex into 2028 while maintaining the $20.0 million minimum liquidity covenant on the Barings facility.

  • EyePoint Suit Settled at No Cost

    The EyePoint defamation and tortious interference action was settled October 30, 2026 with a mutual release and no financial obligation beyond each party paying its own attorneys' fees; no accrual was recorded.


Analysis · OCUL · Life Sciences

The 10-Q confirms the $94.8 million third-quarter loss already reported in this morning's 8-K, but it carries details the headline missed. R&D jumped to $74.8 million from $52.4 million a year earlier as HELIOS-3 and SOL-X enrollment ramped, while revenue slipped to $12.9 million from $14.5 million on higher gross-to-net discounts. The $530.6 million cash balance funds operations into 2028, which covers the planned Q4 2026 AXPAXLI NDA filing without an immediate raise. Two other items matter: the EyePoint defamation suit was settled October 30 with no payment beyond each side's own legal fees, removing a legal overhang, and the SOL-R protocol was amended to move the primary endpoint to Week 40 with masking extended to Week 96 — a change the company says preserves trial integrity ahead of the interim safety analysis. The stock sits near its 52-week low of $6.00, so the market is already pricing skepticism about the NDA and launch; the cash position is what keeps the story alive until the filing.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OCUL was trading at $6.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $6.00 to $16.44. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OCUL - Latest Insights

OCUL
Nov 09, 2026, 7:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.06
Real-time Price: $6.20 info
Change: +$0.1402 (+2%) info
Market Cap: $1.448B info
OCUL
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $6.59
Real-time Price: $6.20 info
Change: -$0.390 (-6%) info
Market Cap: $1.448B info
OCUL
Sep 15, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.76
Real-time Price: $6.20 info
Change: -$4.56 (-42%) info
Market Cap: $1.448B info
OCUL
Aug 03, 2026, 7:16 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.27
Real-time Price: $6.20 info
Change: -$2.07 (-25%) info
Market Cap: $1.448B info
OCUL
Aug 03, 2026, 7:07 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.35
Real-time Price: $6.20 info
Change: -$2.15 (-26%) info
Market Cap: $1.448B info